S G Schumacher1, B Thangakunam2, C M Denkinger3, A A Oliver2, K B Shakti2, Z Z Qin1, J S Michael4, R Luo5, M Pai1, D J Christopher2. 1. McGill University Department of Epidemiology & Biostatistics, Montreal, Canada; McGill International TB Centre, Montreal, Quebec, Canada. 2. Department of Pulmonary Medicine, Christian Medical College Vellore, India. 3. McGill University Department of Epidemiology & Biostatistics, Montreal, Canada; McGill International TB Centre, Montreal, Quebec, Canada; Division of Infectious Disease, Beth Israel Deaconess Medical Centre, Boston, Massachusetts, USA. 4. Department of Microbiology, Christian Medical College, Vellore, India. 5. Department of Pathology, Stanford University, Stanford, California, USA.
Abstract
BACKGROUND: Both product innovation (e.g., more sensitive tests) and process innovation (e.g., a point-of-care [POC] testing programme) could improve patient outcomes. OBJECTIVE: To study the respective contributions of product and process innovation in improving patient outcomes. DESIGN: We implemented a POC programme using Xpert(®) MTB/RIF in an out-patient clinic of a tertiary care hospital in India. We measured the impact of process innovation by comparing time to diagnosis with routine testing vs. POC testing. We measured the impact of product innovation by comparing accuracy and time to diagnosis using smear microscopy vs. POC Xpert. RESULTS: We enrolled 1012 patients over a 15-month period. Xpert had high accuracy, but the incremental value of one Xpert over two smears was only 6% (95%CI 3-12). Implementing Xpert as a routine laboratory test did not reduce the time to diagnosis compared to smear-based diagnosis. In contrast, the POC programme reduced the time to diagnosis by 5.5 days (95%CI 4.3-6.7), but required dedicated staff and substantial adaptation of clinic workflow. CONCLUSION: Process innovation by way of a POC Xpert programme had a greater impact on time to diagnosis than the product per se, and can yield important improvements in patient care that are complementary to those achieved by introducing innovative technologies.
BACKGROUND: Both product innovation (e.g., more sensitive tests) and process innovation (e.g., a point-of-care [POC] testing programme) could improve patient outcomes. OBJECTIVE: To study the respective contributions of product and process innovation in improving patient outcomes. DESIGN: We implemented a POC programme using Xpert(®) MTB/RIF in an out-patient clinic of a tertiary care hospital in India. We measured the impact of process innovation by comparing time to diagnosis with routine testing vs. POC testing. We measured the impact of product innovation by comparing accuracy and time to diagnosis using smear microscopy vs. POC Xpert. RESULTS: We enrolled 1012 patients over a 15-month period. Xpert had high accuracy, but the incremental value of one Xpert over two smears was only 6% (95%CI 3-12). Implementing Xpert as a routine laboratory test did not reduce the time to diagnosis compared to smear-based diagnosis. In contrast, the POC programme reduced the time to diagnosis by 5.5 days (95%CI 4.3-6.7), but required dedicated staff and substantial adaptation of clinic workflow. CONCLUSION: Process innovation by way of a POC Xpert programme had a greater impact on time to diagnosis than the product per se, and can yield important improvements in patient care that are complementary to those achieved by introducing innovative technologies.
Authors: Samuel G Schumacher; William A Wells; Mark P Nicol; Karen R Steingart; Grant Theron; Susan E Dorman; Madhukar Pai; Gavin Churchyard; Lesley Scott; Wendy Stevens; Pamela Nabeta; David Alland; Karin Weyer; Claudia M Denkinger; Christopher Gilpin Journal: J Infect Dis Date: 2019-10-08 Impact factor: 5.226
Authors: Richard J Lessells; Graham S Cooke; Nuala McGrath; Mark P Nicol; Marie-Louise Newell; Peter Godfrey-Faussett Journal: Am J Respir Crit Care Med Date: 2017-10-01 Impact factor: 21.405
Authors: Jason M Bacha; Katherine Ngo; Petra Clowes; Heather R Draper; Elias N Ntinginya; Andrew DiNardo; Chacha Mangu; Issa Sabi; Bariki Mtafya; Anna M Mandalakas Journal: BMC Infect Dis Date: 2017-02-06 Impact factor: 3.090
Authors: Prem Perumal; Mohamed Bilal Abdullatif; Harriet N Garlant; Isobella Honeyborne; Marc Lipman; Timothy D McHugh; Jo Southern; Ronan Breen; George Santis; Kalaiarasan Ellappan; Saka Vinod Kumar; Harish Belgode; Ibrahim Abubakar; Sanjeev Sinha; Seshadri S Vasan; Noyal Joseph; Karen E Kempsell Journal: Front Immunol Date: 2021-03-16 Impact factor: 7.561